SCHEMBL7067097

SCHEMBL7067097

CCCC(C(N)=O)C(CC(C)C)C(=O)N1CCN(c2cccc(C)c2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 3/20 0.45
APP P05067 1/20 0.44
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
LMNA P02545 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TGM2 P21980 1/20 0.41
HTT P42858 1/20 0.40
HTR1A P08908 1/20 0.40
HTR2A P28223 1/20 0.40
HTR7 P34969 1/20 0.40
HTR6 P50406 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7067098 1.00 P2RY12 (0.45) P2RY12APPCA12CA1CA2
SCHEMBL7069249 0.89 LMNA (0.55) CA12CA1CA9LMNAALDH1A1
SCHEMBL7069253 0.89 LMNA (0.55) CA12CA1CA9LMNAALDH1A1
SCHEMBL7087657 0.88 GAA (0.51) APPLMNAALDH1A1MAPTTSHR
SCHEMBL7087655 0.88 GAA (0.51) APPLMNAALDH1A1MAPTTSHR
SCHEMBL7066754 0.88 DRD2 (0.47) APPCA12CA1CA2CA9
SCHEMBL7066757 0.88 DRD2 (0.47) APPCA12CA1CA2CA9
SCHEMBL7069866 0.87 POLB (0.45) LMNAALDH1A1MAPTTSHRHTT
SCHEMBL7069863 0.87 POLB (0.45) LMNAALDH1A1MAPTTSHRHTT
SCHEMBL7068799 0.86 MAPT (0.46) LMNAALDH1A1MAPTTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production THOMPSON LORIN A (US) 2003-12-18 US disclosed
US-20030073701-A1 Succinoylamino heterocycles as inhibitors of a beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073701-A1 Succinoylamino heterocycles as inhibitors of a beta protein production APP, BACE1, APH1A P2RY12 4404/4885APP 1/4885CA12 4206/4885
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production APP, BACE1, APH1A P2RY12 4404/4885APP 1/4885CA12 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.